Pharmaceutical / Biotech Accounting & Reporting Update Conference 2013

DAY ONE AGENDA

Deluxe Continental Breakfast & Registration
8:00 – 8:45 AM

Welcome & Opening Remarks
8:45 – 9:00 AM

Keynote Speaker
9:00 – 9:30 AM

FASB & Technical Accounting Update
9:30 – 10:30 AM
• FASB/IASB update
  – Key projects: summary and timeline
  – Revenue recognition
  – Leases
  – Financial instruments
• Revenue recognition challenges under current GAAP
  – Collaborative arrangement considerations
  – Gross-to-net deductions
  – Refunds
  – Rights of return
  – Contingencies
  – Stand-alone value

Break
10:30 – 10:45 AM

FASB & Technical Accounting Update (continued)
10:45 AM – 12:45 PM
• Income taxes
  – Valuation allowances
  – R&D tax credits
  – Fiscal cliff legislation
• Business combinations and impairments
• Other industry hot topics
  – Medical device excise tax

Luncheon
12:45 – 1:30 PM

Regulatory Update: Aggregate Spend Reporting & the Sunshine Act
1:30 – 2:45 PM
• Update/status of the proposed changes to the Sunshine Act
• Issues within the Spend Reporting Compliance Continuum
• Aggregate spend disputes and inquiries from health care professionals

Break
2:45 – 3:00 PM

Valuation Considerations
3:00 – 4:00 PM
• M&A and intangible asset valuations
• Alternative methodologies for IPR&D valuation
• Discount rate considerations
• Inventory valuation and complexities in the pharmaceutical industry
• Contingent consideration: accounting treatment and royalty arrangements
• Day Two impairment considerations and “Step 0”

Working Capital
4:00 – 4:45 PM

Cocktail Reception
4:45 – 5:45 PM
 

DAY TWO AGENDA

Deluxe Continental Breakfast
8:00 – 8:30 AM

The Pharma/Biotech Market Today & Tomorrow
8:30 – 9:30 AM
• Current health of the industry
• Key drivers
• Emerging trends
• Returns in R&D
• Regulatory and legislative outlook

Health Care Reform Update
9:30 – 10:30 AM
• Proposed or final rules, if available, for AMP and BP and the overall impact to the Medicaid Drug
  Program
• Potential impact on AMP calculation methodology and Medicaid rebate liabilities
• Emerging industry best practices to address the proposed rules

Break
10:30 – 10:45 AM

Health Care Reform Update (continued)
10:45 – 11:45 AM
• Preparations that will be necessary to comply with proposed new rules
• Best practices for compliance
• Gross-to-net accounting
  – Best practices for estimating and reporting gross-to-net deductions (chargebacks, rebates,
     returns and other discounts)
  – Issues and solutions

M&A Update: Current Trends & Best Practices
11:45 AM – 12:45 PM
• M&A best practices
  – Due diligence
  – Contract support
  – Closing and integration
• Key diligence issues in emerging markets
  – Trends in licensing terms

Luncheon
12:45 – 1:30 PM

SEC Hot Topics Affecting Pharmaceutical & Biotech Companies
1:30 – 3:00 PM
An in-depth discussion of reporting standards and the most common areas of focus and comments from the SEC most relevant to pharmaceutical and biotech companies including:

• Perspectives on the development in global standards and reporting, including IFRS
• Updates on the SEC review process
• Frequent SEC comments and areas of focus

Break
3:00 – 3:15 PM

Patient Protection and Affordable Care Act
3:15 – 4:30 PM
• Overview of the Patient Protection and Affordable Care Act
• W-2 reporting requirements
• Exchange notice
• Patient centered outcomes research trust
• Reinsurance contribution
• Employer shared responsibility
• Affordable coverage
• Minimum value: 2014
• Penalty: 2014
• Medicare tax on unearned investment income
• Additional Medicare tax on high income taxpayers
• 2014: individual mandate

Conference Ends
4:30 PM